PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
5.20
+0.46 (9.70%)
At close: Aug 14, 2026, 4:00 PM EDT
5.27
+0.07 (1.35%)
After-hours: Aug 14, 2026, 7:34 PM EDT
PAVmed Revenue
PAVmed had revenue of $33.00K in the quarter ending June 30, 2026, with 450.00% growth. This brings the company's revenue in the last twelve months to $112.00K, down -89.02% year-over-year. In the year 2025, PAVmed had annual revenue of $71.00K, down -97.63%.
Revenue (ttm)
$112.00K
Revenue Growth
-89.02%
P/S Ratio
332.38
Revenue / Employee
$2,732
Employees
41
Market Cap
37.23M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 71.00K | -2.92M | -97.63% |
| Dec 31, 2024 | 3.00M | 543.00K | 22.15% |
| Dec 31, 2023 | 2.45M | 2.08M | 550.40% |
| Dec 31, 2022 | 377.00K | -123.00K | -24.60% |
| Dec 31, 2021 | 500.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 428.57M |
| Nortech Systems | 124.65M |
| Xtant Medical Holdings | 109.53M |
| TELA Bio | 79.91M |
| SANUWAVE Health | 44.02M |
| QT Imaging Holdings | 26.43M |
| Baird Medical Investment Holdings | 22.54M |
| Pulsenmore | 12.55M |
PAVM News
- 15 hours ago - PAVmed Earnings Call Transcript: Q2 2026 - Transcripts
- 15 hours ago - PAVmed Quarterly report: Q2 2026 - Filings
- 15 hours ago - PAVmed Earnings release: Q2 2026 - Filings
- 15 hours ago - PAVmed Slides: Q2 2026 - Filings
- 16 hours ago - PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PRNewsWire
- 1 day ago - Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PRNewsWire
- 9 days ago - Lucid announces Concert issued positive coverage policy for EsoGuard test - TheFly
- 9 days ago - Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test - PRNewsWire